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journal homepage: www.europeanurology.com/euf ocusOver the last 10 yr, multiparametric magnetic resonance
imaging (mp-MRI) has been suggested as a diagnostic test
capable of detecting and ruling out clinically significant
gland-confined prostate cancer before biopsy. The poor
methodologic quality of many initial studies [1,2] led to the
need for a large robust programme of research to evaluate
its clinical validity and utility within the pathway [3]. The
PICTURE [4] and Prostate MR Imaging Study (PROMIS) [3]
trials met this research need.
Although there has been significant improvement in
the literature on mp-MRI, there remain limitations when
evaluating clinical validity (sensitivity, specificity, and
positive and negative predictive values). For instance, many
recent publications have limited sample sizes [5–10] with no
a prior power calculations. Many used histologic reference
standards such as transrectal ultrasound (TRUS) biopsy
[11–13], MRI-guided biopsy, and/or limited sampling with
the biopsy operators unblinded to the MRI results [10,14,15].
Other studies only triggered biopsies when there was an
abnormality on mp-MRI [5,7–9]. This limits the ability to
comment on negative predictive value and introduces
operator bias. These factors, among others such as changing
technology, reader variability, and variable mp-MRI practice* Corresponding author. Division of Surgery and Interventional Science, Univ
UK. Tel. +44 741 1938521.
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creativecommons.org/licenses/by/4.0/).and protocols, contributed to the variability of results on
meta-analysis [16,17].
PROMIS [3] is a multicentre paired-cohort diagnostic
trial funded by the National Institute for Health Research
Health Technology Assessment and Prostate Cancer UK. A
total of 714 biopsy-naı¨ve patients are undergoing optimised
guideline-compliant [18] mp-MRI followed by combined
5-mm transperineal mapping biopsies and a 12-core TRUS
biopsy under general anaesthetic in the same setting.
PROMIS will provide level 1b evidence [19] on the
accuracy of mp-MRI that overcomes the limitations of the
current literature [3]. PROMIS will assess the costs and cost-
benefit of a prebiopsy MRI pathway (Fig. 1), as well as
interobserver variability. Among other outcomes biobank-
ing of serum, plasma, whole blood, and urine will provide
samples for the development and validation of biochemical
markers.
This diagnostic trial set up in multiple centres proved to
be a challenge, with many unforeseen obstacles.
 Scanner set-up and qualification: PROMIS uses 1.5-T
scanners, the most readily available in most centres.
Each scanner had to be optimised in each centre inersity College London, 4th Floor, 132 Hampstead Road, London NW1 2BX,
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Fig. 1 – Potential clinical impact of the PROMIS study. mp-MRI = multiparametric magnetic resonance imaging; TRUS = transrectal ultrasound;
signif = significant.
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over sometimes weeks and months. We noted significant
differences between scanners from the same manufac-
turer, and even scanners of the same model. These
differences required further changes to imaging param-
eters to remain compliant with international guidelines;
one scanner by a certain manufacturer had to be excluded
from the study as we were unable to obtain acceptable
diffusion sequences after several iterations. These factors
will allow us to assess how variations in scanner make,
model, and condition may impact on subsequent diffu-
sion and dissemination within the UK and beyond.
 Lack of essential MRI and interventional ultrasound skills:
To assure correct implementation of a standardised
operating procedure in each trial intervention, the lead
radiologist formally trained the participating radiologists
and held several formal and informal meetings since trial
inception to maintain quality control and address issuesas they arose. Similarly, each site was required to observe
the combined biopsy procedure at trained sites and
subsequently required supervision of the conduct of the
biopsies.
 Running a surgical trial: As a surgical interventional study,
issues with respect to resource use arose. First, the mp-
MRI standardisation process revealed that some centres
were not using gadolinium dynamic contrast enhance-
ment, and the additional 15 min of scan time impacted on
scanner capacity. Second, the combined biopsy procedure
required between 60 and 90 min of operating theatre
time. Third, with a growing body of literature pointing to
the positive role of mp-MRI, there were an increasing
number of physicians and patients lacking equipoise for
the trial.
PROMIS recruitment is on track, with only a 6-mo
extension to our original predicted end date. From
E U R O P E A N U R O L O G Y F O C U S 1 ( 2 0 1 5 ) 2 1 2 – 2 1 421411 centres across the UK, 578 patients have been recruited
and 98 have withdrawn up to April 2015. Recruitment is
due to end in October/November 2015.
PROMIS will provide an once-in-a-lifetime opportunity to
evaluate the diagnostic accuracy of mp-MRI based on an
adequately large sample size and a highly accurate reference
test in comparison to standard TRUS biopsy. The biobank of
tissue, imaging data, serum, and urine will offer a uniquely
validated data set for further translational research.
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